Key result
Vinpocetine cuts hypertensive aortic contraction ~44% and restores vascular cGMP levels.
Why the study?
Does PDE1 inhibition with vinpocetine restore vascular cGMP bioavailability and reduce augmented arterial contractility in rats with Angiotensin II-induced hypertension?
Does PDE1 inhibition with vinpocetine restore vascular cGMP bioavailability and reduce augmented arterial contractility in rats with Angiotensin II-induced hypertension?
Answers are grounded in this paper and cite their sources.
Chronic Angiotensin II infusion upregulates vascular PDE1 expression and activity, depleting cGMP and increasing arterial contractility, which can be reversed ex vivo by PDE1 inhibition with vinpocetine.
Recent evidence suggests that angiotensin II (Ang II) upregulates phosphodiesterase (PDE) 1A expression. We hypothesized that Ang II augmented PDE1 activation, decreasing the bioavailability of cyclic guanosine 3' 5'-monophosphate (cGMP), and contributing to increased vascular contractility. Male Sprague-Dawley rats received mini-osmotic pumps with Ang II (60 ng·min(-1)) or saline for 14 days. Phenylephrine (PE)-induced contractions were increased in aorta (E(max)168% ± 8% vs 136% ± 4%) and small mesenteric arteries (SMA; E(max)170% ± 6% vs 143% ± 3%) from Ang II-infused rats compared to control. PDE1 inhibition with vinpocetine (10 μmol/L) reduced PE-induced contraction in aortas from Ang II rats (E(max)94% ± 12%) but not in controls (154% ± 7%). Vinpocetine decreased the sensitivity to PE in SMA from Ang II rats compared to vehicle (-log of half maximal effective concentration 5.1 ± 0.1 vs 5.9 ± 0.06), but not in controls (6.0 ± 0.03 vs 6.1 ± 0.04). Sildenafil (10 μmol/L), a PDE5 inhibitor, reduced PE-induced maximal contraction similarly in Ang II and control rats. Arteries were contracted with PE (1 μmol/L), and concentration-dependent relaxation to vinpocetine and sildenafil was evaluated. Aortas from Ang II rats displayed increased relaxation to vinpocetine compared to control (E(max)82% ± 12% vs 445 ± 5%). SMA from Ang II rats showed greater sensitivity during vinpocetine-induced relaxation compared to control (-log of half maximal effective concentration 6.1 ± 0.3 vs 5.3 ± 0.1). No differences in sildenafil-induced relaxation were observed. PDE1A and PDE1C expressions in aorta and PDE1A expression in SMA were increased in Ang II rats. cGMP production, which is decreased in arteries from Ang II rats, was restored after PDE1 blockade. We conclude that PDE1 activation reduces cGMP bioavailability in arteries from Ang II, contributing to increased contractile responsiveness.
No takes yet. Share an insight, caveat, or question.
Giachini et al. (2011) studied Angiotensin II-induced hypertension. Angiotensin II infusion and ex vivo PDE1 inhibition with vinpocetine vs. Saline infusion (8.33 nL/min) and ex vivo vehicle or sildenafil (10 µmol/L) was evaluated on Phenylephrine-induced maximum contraction (Emax) in isolated endothelium-denuded aorta after PDE1 inhibition with vinpocetine (p=<0.0001). PDE1 inhibition with vinpocetine reduced phenylephrine-induced maximal aortic contraction in Angiotensin II-hypertensive rats from 168% to 94% and restored vascular cGMP levels.
Synapse has enriched 10 related papers. Consider them for comparative context: